Collectively, we proposed that the ERK1/2-MNK1 axis is required for bilirubin-induced reversal of growth inhibition and apoptosis induction in BRAF mutant melanoma following vemurafenib treatment. The gene discussed is MKNK1; the disease is melanoma.